BASEL, Switzerland - Windward Bio Group AG closed its Nasdaq initial public offering and a concurrent private placement on Nov. 16, raising about $251.2 million in gross proceeds.
Full Option Exercise and Sanofi Investment
Windward Bio sold 11,838,234 common shares at $17.00 per share, including the underwriters' full exercise of their option to buy 1,544,117 additional shares. Separately, Sanofi Foreign Participations B.V. invested $50.0 million in a concurrent private placement at the same $17.00 price, acquiring 1,532,691 shares and pre-funded warrants for 1,408,485 shares. 16 closing release.
Trading Debut and Respiratory Pipeline
Shares of Windward Bio, trading under the ticker WWB, began trading on Nov. 13 and surged 68% on debut to a first-day market value near $1.69 billion. Founded in 2024 by Chief Executive Luca Santarelli, M.D., the Basel-based company develops ultra-long-acting biologics for respiratory and immunological diseases. Its lead candidate, WIN378, is a twice-yearly anti-TSLP antibody in the Phase 2/3 POLARIS-1 asthma trial and the Phase 2 SIRIUS study for chronic obstructive pulmonary disease, alongside Phase 1 bispecific antibody WIN027.
Cross-Border Licensing and Funding Use
Windward Bio built its pipeline by licensing antibodies discovered by Chinese biotechs including Harbour BioMed, Kelun-Biotech, and Qyuns Therapeutics with backing from investors such as Novo Holdings. Proceeds from the offering will fund ongoing global clinical trials for WIN378 and WIN027 and support potential expansion into additional immune-mediated diseases.



